Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation

BMC Cardiovascular Disorders

Volumn 11, Issue , 2011, Pages

  Kalogeropoulos, Andreas S ^a   Tsiodras, Sotirios ^b   Rigopoulos, Angelos G ^b   Sakadakis, Eleftherios A ^b   Triantafyllis, Andreas ^b   Kremastinos, Dimitrios T H ^b   Rizos, Ioannis ^b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BIOLOGICAL MARKER; TIMP1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BODY SURFACE; CARDIAC REMODELING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ESSENTIAL HYPERTENSION; FEMALE; HEART ATRIUM FIBRILLATION; HEART FUNCTION; HEART VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PAROXYSMAL HEART ATRIUM FIBRILLATION; PERMANENT HEART ATRIUM FIBRILLATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SINUS RHYTHM; SYSTOLE; UPREGULATION; BLOOD; CASE CONTROL STUDY; HEART VENTRICLE REMODELING; HYPERTENSION; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR REMODELING;

EID: 84455193363     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-11-77     Document Type: Article

References (46)

1. van den Berg MP, van Gelder IC, van Veldhuisen DJ. Impact of atrial fibrillation on mortality in patients with chronic heart failure. Eur J Heart Fail 2002, 4(5):571-575. 10.1016/S1388-9842(02)00094-6, 12413498.
2. Sun H, Gaspo R, Leblanc N, Nattel S. Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia. Circulation 1998, 98(7):719-727.
3. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002, 54(2):230-246. 10.1016/S0008-6363(02)00258-4, 12062329.
4. Brundel BJ, Henning RH, Kampinga HH, Van Gelder IC, Crijns HJ. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 2002, 54(2):315-324. 10.1016/S0008-6363(02)00222-5, 12062337.
5. Rizos I, Tsiodras S, Rigopoulos AG, Dragomanovits S, Kalogeropoulos AS, Papathanasiou S, Sakadakis EA, Kremastinos DT. Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. Cytokine 2007, 40(3):157-164. 10.1016/j.cyto.2007.08.013, 17923414.
6. Rizos I, Rigopoulos AG, Kalogeropoulos AS, Tsiodras S, Dragomanovits S, Sakadakis EA, Faviou E, Kremastinos DT. Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence. J Hum Hypertens 24(7):447-457.
7. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995, 92(7):1954-1968.
8. Morillo CA, Klein GJ, Jones DL, Guiraudon CM. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995, 91(5):1588-1595.
9. Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S. Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation 2002, 105(22):2672-2678. 10.1161/01.CIR.0000016826.62813.F5, 12045175.
10. Boixel C, Fontaine V, Rucker-Martin C, Milliez P, Louedec L, Michel JB, Jacob MP, Hatem SN. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 2003, 42(2):336-344. 10.1016/S0735-1097(03)00578-3, 12875773.
11. Marin F, Roldan V, Climent V, Garcia A, Marco P, Lip GY. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?. Stroke 2003, 34(5):1181-1186. 10.1161/01.STR.0000065431.76788.D9, 12663879.
12. Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ, Spinale FG, Gold MR. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 2006, 97(4):532-537. 10.1016/j.amjcard.2005.08.073, 16461051.
13. Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F, Ishida M, Shingu T, Sueda T, Yoshizumi M, et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 2004, 43(5):818-825. 10.1016/j.jacc.2003.08.060, 14998623.
14. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, Odim J, Laks H, Sen L. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004, 109(3):363-368. 10.1161/01.CIR.0000109495.02213.52, 14732752.
15. Gramley F, Lorenzen J, Plisiene J, Rakauskas M, Benetis R, Schmid M, Autschbach R, Knackstedt C, Schimpf T, Mischke K, et al. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol 2007, 18(10):1076-1082. 10.1111/j.1540-8167.2007.00906.x, 17655664.
16. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57(6):450-458. 10.1016/0002-9149(86)90771-X, 2936235.
17. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987, 59(9):956-960. 10.1016/0002-9149(87)91133-7, 2952002.
18. Lester SJ, Ryan EW, Schiller NB, Foster E. Best method in clinical practice and in research studies to determine left atrial size. Am J Cardiol 1999, 84(7):829-832. 10.1016/S0002-9149(99)00446-4, 10513783.
19. Wang Y, Gutman JM, Heilbron D, Wahr D, Schiller NB. Atrial volume in a normal adult population by two-dimensional echocardiography. Chest 1984, 86(4):595-601. 10.1378/chest.86.4.595, 6236959.
20. Pritchett AM, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM. Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol 2003, 41(6):1036-1043. 10.1016/S0735-1097(02)02981-9, 12651054.
21. Bellet S. Clinical disorders of the heart beat. 1971, Philadelphia,: Lea & Febiger, 3.
22. Aime-Sempe C, Folliguet T, Rucker-Martin C, Krajewska M, Krajewska S, Heimburger M, Aubier M, Mercadier JJ, Reed JC, Hatem SN. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999, 34(5):1577-1586. 10.1016/S0735-1097(99)00382-4, 10551709.
23. Thijssen VL, Ausma J, Liu GS, Allessie MA, van Eys GJ, Borgers M. Structural changes of atrial myocardium during chronic atrial fibrillation. Cardiovasc Pathol 2000, 9(1):17-28. 10.1016/S1054-8807(99)00038-1, 10739903.
24. Miyauchi Y, Zhou S, Okuyama Y, Miyauchi M, Hayashi H, Hamabe A, Fishbein MC, Mandel WJ, Chen LS, Chen PS, et al. Altered atrial electrical restitution and heterogeneous sympathetic hyperinnervation in hearts with chronic left ventricular myocardial infarction: implications for atrial fibrillation. Circulation 2003, 108(3):360-366. 10.1161/01.CIR.0000080327.32573.7C, 12835207.
25. Tanaka K, Zlochiver S, Vikstrom KL, Yamazaki M, Moreno J, Klos M, Zaitsev AV, Vaidyanathan R, Auerbach DS, Landas S, et al. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res 2007, 101(8):839-847. 10.1161/CIRCRESAHA.107.153858, 17704207.
26. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997, 96(9):3157-3163.
27. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002, 54(2):361-379. 10.1016/S0008-6363(02)00273-0, 12062341.
28. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002, 415(6868):219-226. 10.1038/415219a, 11805846.
29. Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol 2005, 13(3):181-193. 10.1007/s10840-005-2362-y, 16177845.
30. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69(3):562-573. 10.1016/j.cardiores.2005.12.002, 16405877.
31. Hoit BD. Matrix metalloproteinases and atrial structural remodeling. J Am Coll Cardiol 2003, 42(2):345-347. 10.1016/S0735-1097(03)00585-0, 12875774.
32. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000, 35(6):1669-1677. 10.1016/S0735-1097(00)00611-2, 10807475.
33. Rouet-Benzineb P, Gontero B, Dreyfus P, Lafuma C. Angiotensin II induces nuclear factor- kappa B activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol 2000, 32(10):1767-1778. 10.1006/jmcc.2000.1211, 11013121.
34. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000, 101(22):2612-2617.
35. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000, 46(2):214-224. 10.1016/S0008-6363(00)00003-1, 10773225.
36. Lin CS, Pan CH. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 2008, 65(10):1489-1508. 10.1007/s00018-008-7408-8, 18322650.
37. Chen CL, Huang SK, Lin JL, Lai LP, Lai SC, Liu CW, Chen WC, Wen CH, Lin CS. Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J Mol Cell Cardiol 2008, 45(6):742-753. 10.1016/j.yjmcc.2008.07.007, 18692064.
38. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Arfanakis DA, Maliaraki NE, Lathourakis CE, Chlouverakis GI, Vardas PE. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. J Am Coll Cardiol 2008, 52(3):211-215. 10.1016/j.jacc.2008.03.045, 18617070.
39. Lin JL, Lai LP, Lin CS, Du CC, Wu TJ, Chen SP, Lee WC, Yang PC, Tseng YZ, Lien WP, et al. Electrophysiological mapping and histological examinations of the swine atrium with sustained (> or = 24 h) atrial fibrillation: a suitable animal model for studying human atrial fibrillation. Cardiology 2003, 99(2):78-84. 10.1159/000069728, 12711882.
40. Kamalvand K, Tan K, Lloyd G, Gill J, Bucknall C, Sulke N. Alterations in atrial electrophysiology associated with chronic atrial fibrillation in man. Eur Heart J 1999, 20(12):888-895. 10.1053/euhj.1998.1404, 10329094.
41. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999, 100(1):87-95.
42. Mountain DJ, Singh M, Menon B, Singh K. Interleukin-1beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: role of PKCalpha/beta1 and MAPKs. Am J Physiol Cell Physiol 2007, 292(2):C867-875.
43. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002, 106(12):1543-1549. 10.1161/01.CIR.0000028818.33488.7B, 12234962.
44. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, Szczesna-Cordary D, Schulz R. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 2005, 112(4):544-552. 10.1161/CIRCULATIONAHA.104.531616, 16027249.
45. Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, Lovett DH. A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J 2003, 369(Pt 3):485-496. 1223099, 12371906.
46. Alfonso-Jaume MA, Bergman MR, Mahimkar R, Cheng S, Jin ZQ, Karliner JS, Lovett DH. Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol 2006, 291(4):H1838-1846. 10.1152/ajpheart.00026.2006, 16699069.